TrialJournal of hepatology2022

Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.

Naim Alkhouri et al.PubMed ↗Publisher ↗

No numbers read from the abstract.